CELLSEEKER

Serial Number 98795718
641

Registration Progress

Application Filed
Oct 10, 2024
Under Examination
Approved for Publication
Published for Opposition
Registered

Trademark Image

CELLSEEKER

Basic Information

Serial Number
98795718
Filing Date
October 10, 2024
Drawing Code
4

Status Summary

Current Status
Active
Status Code
641
Status Date
Apr 3, 2025
Application
Pending
Classes
005

Rights Holder

CAPSTAN THERAPEUTICS, INC.

03
Address
9880 Campus Point Drive, Suite 220
San Diego, CA 92121

Ownership History

CAPSTAN THERAPEUTICS, INC.

Original Applicant
03
San Diego, CA

Legal Representation

Attorney
Joi A. White

USPTO Deadlines

No Upcoming Deadlines

No upcoming deadlines found for this trademark.

Application History

8 events
Date Code Type Description Documents
Jun 30, 2025 XELG O APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED Loading...
Jun 30, 2025 XELR I APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED Loading...
Apr 3, 2025 GNRT F NON-FINAL ACTION E-MAILED Loading...
Apr 3, 2025 CNRT R NON-FINAL ACTION WRITTEN Loading...
Apr 3, 2025 GNRN O NOTIFICATION OF NON-FINAL ACTION E-MAILED Loading...
Mar 21, 2025 DOCK D ASSIGNED TO EXAMINER Loading...
Oct 11, 2024 NWOS I NEW APPLICATION OFFICE SUPPLIED DATA ENTERED Loading...
Oct 11, 2024 NWAP I NEW APPLICATION ENTERED Loading...

Detailed Classifications

Class 005
Pharmaceuticals; pharmaceutical preparations; pharmaceutical substances; therapeutics; therapeutic agents; biopharmaceuticals; medicines; drugs; vaccines; systems to express therapeutic proteins in vivo; gene therapy products; gene therapy preparations; in vivo nucleic acid, DNA, RNA, and mRNA technologies; lipid nanoparticles for medicinal use; binding moiety decorated lipid nanoparticles for medicinal use; lipid nanoparticles for durable cell reprogramming or cell engineering; binding moiety decorated lipid nanoparticles for durable cell reprogramming or cell engineering; cell engineering platforms; cell engineering platforms for treatment of human diseases, disorders and conditions; technology platforms for developing and engineering therapeutic cells; in vivo cell engineering platforms; transient in vivo cell engineering platforms for durable gene therapy; technology platforms for transfection, namely, binding moiety decorated lipid nanoparticles for genetic engineering; reagents for transfection; reagents for transfection in vivo; reagents for transfection, namely, binding moiety decorated lipid nanoparticles; technology platforms for delivery of a payload by binding moiety decorated lipid nanoparticles including antibody decorated lipid nanoparticles; technology platforms for delivery of a nucleic acid payload; technology platforms for delivery of a negatively charged payload; biologics delivery systems; biologics delivery platforms; reagents for delivery of a payload by binding moiety decorated lipid nanoparticles including antibody decorated lipid nanoparticles; cell engineering platforms consisting of reagents, lipid nanoparticles, cell receptors, proteins, recombinant protein binders, mRNA, and antibodies or antigen binding portions thereof; biological technology platforms consisting of reagents, lipid nanoparticles, cell receptors, proteins, recombinant protein binders, nucleic acid, DNA, RNA, mRNA, and antibodies or antigen binding portions thereof, for the treatment and prevention of treatment of human diseases, disorders and conditions; chemical reagents for medical uses; clinical medical reagents; reagents for medical use; biological reagents for medical use; binding moiety decorated lipid nanoparticles;

Classification

International Classes
005